skinny.

Latest / Lung Cancer Considered

FDA Approval: Taletrectinib and ROS1 NSCLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.